‘Gavreto’ withdrawn from KOR amid reimb rejection
By Lee, Hye-Kyung | translator Kim, Jung-Ju
24.02.20 12:05:05
가나다라
0
Roche, BPM, the drug’s original developer, made decision to withdraw selling and developing Gavreto last year
Currently, 134 are in stock, and the last import date is expected to be on April 11th
▲BPM made a decision to discontinue selling and developing Gavreto in all countries except the United States and China.
‘Gavreto Cap. 100mg (pralsetinib),’ previously managed by Roche Korea, will be withdrawn from the Korean market.
In February 2023, Roche announced its decision to terminate the global partnership agreement with Blueprint Medicines Corporation (BPM), the drug’s original developer. Furthermore, Gavreto did not clear the reimbursement hurdle, leading to the voluntary withdrawal of its Biologics License Application (BLA).
Gavreto will no longer be available in South Korea as BPM, the original developer of Gavreto, does not hold a division in Korea, and a search for a new partner has been unsuccessful.
“Gavreto has not been prescribed since June 2023, and there are
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)